Paradigm Biopharmaceuticals Ltd.ASX: PAR

Paradigm doses first participant in Synovial Fluid Trial

Apr 14, 2021 at 3:38 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment